Literature DB >> 26329368

Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.

Giandomenico Roviello1, Roberto Petrioli2, Luigi Marano3, Karol Polom3, Daniele Marrelli4, Armando Perrella2, Franco Roviello3.   

Abstract

Despite significant improvements in systemic chemotherapy during the past two decades, the prognosis of patients with advanced gastric and gastroesophageal junction adenocarcinoma remains poor. Because of molecular heterogeneity, it is essential to classify tumors based on the underlying oncogenic pathways and to develop targeted therapies acting on individual tumors. Unfortunately, although a number of molecular targets have been studied, very few of these agents can be used in a clinical setting. In this review, we summarize the available data on anti-angiogenic agents in advanced/metastatic gastric cancer.

Entities:  

Keywords:  Bevacizumab; Gastric cancer; Ramucirumab; VEGF

Mesh：

Substances：

Year:  2015        PMID： 26329368     DOI： 10.1007/s10120-015-0537-5

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


  67 in total

1.  A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

Authors:  B F El-Rayes; M Zalupski; T Bekai-Saab; L K Heilbrun; N Hammad; B Patel; S Urba; A F Shields; U Vaishampayan; S Dawson; K Almhanna; D Smith; P A Philip
Journal:  Ann Oncol       Date:  2010-03-23       Impact factor: 32.976

2.  Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas.

Authors:  N Tanigawa; H Amaya; M Matsumura; T Shimomatsuya; T Horiuchi; R Muraoka; M Iki
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

3.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.

Authors:  Alicia F C Okines; Sue E Ashley; David Cunningham; Jacqueline Oates; Andrea Turner; Janine Webb; Claire Saffery; Yu Jo Chua; Ian Chau
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer.

Authors:  M Moehler; A Mueller; J T Hartmann; M P Ebert; S E Al-Batran; P Reimer; M Weihrauch; F Lordick; T Trarbach; S Biesterfeld; M Kabisch; D Wachtlin; P R Galle
Journal:  Eur J Cancer       Date:  2011-05-09       Impact factor: 9.162

5.  YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.

Authors:  Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin Li; Liguang Lou
Journal:  Cancer Sci       Date:  2011-05-09       Impact factor: 6.716

6.  Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma.

Authors:  K Maeda; S M Kang; N Onoda; M Ogawa; Y Kato; T Sawada; K H Chung
Journal:  Cancer       Date:  1999-08-15       Impact factor: 6.860

7.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

Authors:  Atsushi Ohtsu; Jaffer A Ajani; Yu-Xian Bai; Yung-Jue Bang; Hyun-Cheol Chung; Hong-Ming Pan; Tarek Sahmoud; Lin Shen; Kun-Huei Yeh; Keisho Chin; Kei Muro; Yeul Hong Kim; David Ferry; Niall C Tebbutt; Salah-Eddin Al-Batran; Heind Smith; Chiara Costantini; Syed Rizvi; David Lebwohl; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 8.  Vascular endothelial growth factor as a target for anticancer therapy.

Authors:  Napoleone Ferrara
Journal:  Oncologist       Date:  2004

9.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.

Authors:  Y Takahashi; K R Cleary; M Mai; Y Kitadai; C D Bucana; L M Ellis
Journal:  Clin Cancer Res       Date:  1996-10       Impact factor: 12.531

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more
  23 in total

1.  Bioinformatics evaluation of a novel angiogenesis related genes-based signature for predicting prognosis and therapeutic efficacy in patients with gastric cancer.

Authors:  Ning Ma; Jie Li; Ling Lv; Chunhua Li; Kainan Li; Bin Wang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 2.  Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance.

Authors:  Xiaolin Wang; Jiahui Zhang; Guozhen Cao; Jinghan Hua; Ge Shan; Wenchu Lin
Journal:  J Exp Clin Cancer Res       Date:  2022-07-11

3.  Apatinib regulates the growth of gastric cancer cells by modulating apoptosis and autophagy.

Authors:  Xu Liu; Qiaoyu Zheng; Qiongfang Yu; Yan Hu; Yanmin Cheng; Zhaozhao Shao; Li Chen; Wenjie Ding; Dian Gao
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-18       Impact factor: 3.000

4.  Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Rosa Berenato; Luca Turati; Alessia Mennitto; Francesca Steccanella; Marta Caporale; Pierpaolo Dallera; Filippo de Braud; Ezio Pezzica; Maria Di Bartolomeo; Giovanni Sgroi; Vincenzo Mazzaferro; Filippo Pietrantonio; Sandro Barni
Journal:  J Gastrointest Oncol       Date:  2017-02

5.  Expression of vasohibin-1 and -2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus.

Authors:  Yamato Ninomiya; Soji Ozawa; Junya Oguma; Akihito Kazuno; Miho Nitta; Hiroshi Kajiwara; Yasufumi Sato
Journal:  Oncol Lett       Date:  2018-08-01       Impact factor: 2.967

Review 6.  Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review.

Authors:  Magdalena Tyczyńska; Paweł Kędzierawski; Kaja Karakuła; Jacek Januszewski; Krzysztof Kozak; Monika Sitarz; Alicja Forma
Journal:  J Gastrointest Cancer       Date:  2021-03-24

7.  Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation.

Authors:  Wei Zhang; Yongsheng Tan; Heping Ma
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

Review 8.  Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.

Authors:  Giandomenico Roviello; Karol Polom; Roberto Petrioli; Luigi Marano; Daniele Marrelli; Giovanni Paganini; Vinno Savelli; Daniele Generali; Lorenzo De Franco; Andrea Ravelli; Franco Roviello
Journal:  Tumour Biol       Date:  2015-11-13

9.  Advanced alveolar soft part sarcoma responds to apatinib.

Authors:  Yong Zhou; Fan Tang; Yiying Wang; Li Min; Yi Luo; Wenli Zhang; Rui Shi; Hong Duan; Chongqi Tu
Journal:  Oncotarget       Date:  2017-07-25

10.  Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.

Authors:  Jian-Xian Lin; Yan-Chang Xu; Wei Lin; Fang-Qin Xue; Jian-Xin Ye; Wei-Dong Zang; Li-Sheng Cai; Jun You; Jian-Hua Xu; Jian-Chun Cai; Yi-Hui Tang; Jian-Wei Xie; Ping Li; Chao-Hui Zheng; Chang-Ming Huang
Journal:  JAMA Netw Open       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.